Methotrexate-albumin conjugate causes tumor growth delay in Dunning R3327 HI prostate cancer-bearing rats

Anti-Cancer Drugs

Volumn 10, Issue 4, 1999, Pages 405-411

  Stehle, Gerd ^a   Wunder, Andreas ^b   Schrenk, Hans Herrmann ^a   Hartung, Gernot ^a   Heene, Dieter L ^a,b   Sinn, Hannsjörg ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Albumins; Copenhagen rats; Drug carriers; Dunning prostate cancer; Methotrexate therapy; Methotrexate albumin; Ovarian 342 tumor; Tumor volume doubling time; Walker 256 carcinoma

Indexed keywords

DRUG CARRIER; METHOTREXATE; METHOTREXATE SERUM ALBUMIN; METHOTREXATE-SERUM ALBUMIN; SERUM ALBUMIN;

ANIMAL; ARTICLE; BLOOD; BODY WEIGHT; CELL DIVISION; CELL LINE; DRUG EFFECT; DRUG RESISTANCE; HUMAN; LYSOSOME; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; RAT; TISSUE DISTRIBUTION; XENOGRAFT;

ANIMALS; BODY WEIGHT; CELL DIVISION; CELL LINE; DRUG CARRIERS; DRUG RESISTANCE, NEOPLASM; HUMANS; LYSOSOMES; MALE; METHOTREXATE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RATS; SERUM ALBUMIN; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033112951     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199904000-00009     Document Type: Article

References (23)

1. Gcigy scientific tables: composition of blood. Basle: Ciba Geigy 1984: 78-199.
2. Stellte G, Sinn H, Wunder A, et al. Plasma protein (albumin) catabolism by the tumor itself-implications for tumor metabolism and the genesis of cachexia. Crit Rev Oncol Hcmatol 1997; 26: 77-100.
3. Sinn H, Schrenk HH, Friedrich EA, Sclulling U, Maier Borst W. Design of compounds having an enhanced tumour uptake, using serum albumin as a carrier. Part I. Int J Radiat Appl Instnnn B 1990; 17: 819-27.
4. Andersson C, Iresjo BM, Lundholm K. Identification of tissue sites for increased albumin degradation in sarcomabearing mice.J Sitrg Res 1991; 50: 156-62.
5. Wunder A, Stehle G, Sinn H, et al. Enhanced albumin uptake by rat tumors. IntJ Oncol 1997; 11: 497-507.
6. Clonus JH, Sinn H, Manke HG, etal. Serum albumin (SA) accumulation by bronchogenic tumours: a tracer technique may help with patient selection for SA-delivered chemotherapy. EurJ Nucl Med 1995; 22: 989-96.
7. Stehle G, Sinn H, Wunder A, et al. The loading rate determines tumor targeting of methotrexate-albumin conjugates in rats. Anti-Cancer Dmgs 1997; 8: 677-85.
8. Stehle G, Wunder A, Sinn H, et al. Pharmacokinetics of methotrexate-albumin conjugates in tumor bearing rats. Anti-Cancer Dmgs 1997; 8: 835-44.
9. Wunder A, Stelile G, Schrenk HH, et al. Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinosarcoma. IntJ Cancer 1998; 76: 88490.
10. Dunning WF. Prostate cancer in the rat. NCI Monogr 1963; 12: 351-69.
11. Lolir F, Wenz F, Flentje M, Peschke P, Haiin EW. Measurement of the proliferative activity of three different sublines of the Dunning rat prostate tumor R3327. Strahlcnther Onkol 1993; 169: 438-45.
12. Wenz F, Lolir F, Peschke P, Wolber G, Hover KH, Hahn EW. [The relative biological effectiveness (RBE) of fast neutrons on the Dunning rat prostate carcinoma R3327-HI]. Strahlcnther Onkol 1993; 169: 412-7.
13. Smolev JK, Heston WDW, Scott WW, Coffey DS. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer. Cancer Treat Rep 1977; 61: 273-87.
14. Isaacs JT, Heston WDW, Weissman RM, Coffey DS. Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res 1978; 38: 4353-9.
15. Isaacs JT, Coffey DS. Model systems for the study of prostatic cancer. In: Murphy G, ed. Cancer of the prostate. London: Saunders 1983: 479-98.
16. Sharief Y, Molller JL Genetic instability assessed by sister chromatid exchange analysis in the Dunning R-3327 rat prostatic adenocarcinoma model and its relationship to metastatic potential. Prostate 1995; 26: 247-52.
17. Quarmby VE, Beckman WCJ, Cooke DB, et al. Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Res 1990; 50: 735-9-
18. Fogt F, Wan J, O'Hara C, Bistrian BR, Blackburn GL, Istfan NW. Flow cytometric measurement of cell cycle kinetics in rat Walker-256 carcinoma following in vivo and in vitro pulse labelling with bromodeoxyuridine. Cytoinetiy 1991; 12: 33-41.
19. Lee HB, Blaufox MD. Blood volume in the m.JNuclMed 1985; 26: 72-6.
20. Siegsmund MJ, Kreukler C, Steidler A, Nebe T, Kohrmann KU, Alken P. Multidmg resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein. Urol Res 1997; 25: 35-41.
21. Thorpe SR, Baynes JW, Clironeos ZC. The design and application of residualizing labels for the studies of protein catabolism. FASEBJ 1993; 7: 399-405.
22. Fiebig HH, Roth T, Härtung G, Sinn H, Stehle G. In vivo activity of a methotrexate-albumin conjugate (MTX-HSA) in human tumor xenografts. Enr J Cancer 1997; 33 (suppl 8): S174 (abstr).
23. Härtung G, Stehle G, Sinn H, et al. Phase-1 trial of a methotrexate-albumin conjugate OfTX-HSA) in cancer patients. Eitr J Cancer 1997; 33 (suppl 8) S249-50 (abstr).